High-Dose Therapy and Autologous Stem Cell Transplantation During Remission in Poor-Risk Age-Adjusted International Prognostic Index High and High-Intermediate Risk Group Patients With Intermediate Grade and High-Grade Non-Hodgkin's Lymphoma Including Mantle Cell Lymphoma
16 Years
59 Years
Both
Lymphoma
Trial Information
High-Dose Therapy and Autologous Stem Cell Transplantation During Remission in Poor-Risk Age-Adjusted International Prognostic Index High and High-Intermediate Risk Group Patients With Intermediate Grade and High-Grade Non-Hodgkin's Lymphoma Including Mantle Cell Lymphoma
OBJECTIVES:
- To evaluate the outcome of patients with poor-risk, age-adjusted International
Prognostic Index high- and high-intermediate-risk, intermediate- and high-grade
non-Hodgkin lymphoma undergoing high-dose therapy comprising etoposide and
cyclophosphamide, either carmustine or total-body irradiation, and autologous stem cell
transplantation (ASCT) given as a consolidation therapy.
- To evaluate the role of high-dose therapy and ASCT during first partial or complete
remission (1PR/CR) in patients with poor-risk primary mediastinal large cell lymphoma.
- To evaluate the role of high-dose therapy and ASCT during first 1PR/CR in patients with
advanced-stage mantle cell lymphoma.
- To evaluate the short-term and long-term toxicities of high-dose therapy and ASCT when
performed during 1PR/CR in patients with poor-risk aggressive lymphomas.
OUTLINE: Patients are stratified according to disease (diffuse mixed, diffuse large cell,
and immunoblastic lymphoma vs primary mediastinal large cell lymphoma vs small noncleaved
cell lymphoma vs stage IV mantle cell lymphoma).
Patients' peripheral blood stem cells (PBSC) are collected after mobilization. A minimum of
2.0 x 10^6 CD34+ cells/kg must be collected. Patients experiencing disease progression
during stem cell collection will be removed from study. Patients are assigned to undergo 1
of 2 therapeutic regimens.
- Regimen 1: Patients undergo total-body irradiation (TBI) on days -8 to -5 and receive
etoposide IV over 4 hours on day -4 and cyclophosphamide IV over 2 hours on day -2.
Patients undergo autologous PBSC transplantation on day 0.
- Regimen 2 (for patients who have received any prior thoracic irradiation or patients
who underwent previous irradiation that precludes the use of TBI): Patients receive
carmustine IV over 2 hours on days -7 to -5. Patients then receive etoposide and
cyclophosphamide and undergo autologous PBSC transplantation as in regimen 1.
Patients with residual bulky disease greater than 5 cm may undergo involved-field
radiotherapy before or after transplantation.
Patients are followed at days 7, 14, 21, 100 and 180 after PBSC transplantation, every 6
months for 3 years, and then annually thereafter.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Biopsy-proven diagnosis of high-grade (small noncleaved cell lymphoma [SNCCL] or
immunoblastic lymphoma) or intermediate-grade non-Hodgkin lymphoma (NHL) including
mantle cell lymphoma (MCL)
- SNCCL patients with all of the following factors at presentation of disease:
- Lactate dehydrogenase (LDH) > 500 IU/L
- Unresectable bulky mass > 10 cm
- Stage IV disease with bone marrow involvement
- MCL Patients with stage IV disease or in International Prognostic Index (IPI)
high- or high-intermediate-risk group at the time of diagnosis
- Considered at diagnosis to be high- (3 risk factors) or high-intermediate-risk (2
risk factors) based on an age-adjusted IPI
- Poor prognostic factors at diagnosis include stage III or IV disease, lactate
dehydrogenase (LDH) level above normal, or ECOG performance status (PS) 2-4
- Patients with primary mediastinal large cell lymphoma with or without sclerosis who
at diagnosis had elevated LDH level with bulky mediastinal mass > 10 cm associated
with a pleural effusion on chest radiography or computer tomography, or who have
persistent mediastinal mass with positive disease by post-treatment gallium GA 67
scan
- Must have attained a complete response or partial response to first-line standard
conventional chemotherapy
- No evidence of lymphoma or < 10% lymphomatous involvement of bone by bilateral
bone marrow aspiration and biopsy
- No abnormal cytogenetic study of bone marrow aspirate sample NOTE: A new
classification scheme for adult non-Hodgkin lymphoma has been adopted by PDQ.
The terminology of "indolent" or "aggressive" lymphoma will replace the former
terminology of "low", "intermediate", or "high" grade lymphoma. However, this
protocol uses the former terminology.
PATIENT CHARACTERISTICS:
- ECOG PS 0-1 OR Karnofsky PS 80-100%
- Serum creatinine < 1.5 mg/dL OR creatinine clearance > 60 mL/min
- FEV_1 > 65% of predicted measurement or DLCO ≥ 45% of predicted measurement
- Cardiac ejection fraction > 50% by echocardiogram
- Bilirubin ≤ 1.5 x normal
- SGOT or SGPT ≤ 2 x normal
- Negative HIV antibody
- No prior malignancies except for adequately treated basal cell or squamous cell
carcinoma of the skin
- No hepatitis B surface antigen positivity
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No prior bone marrow transplantation
Type of Study:
Interventional
Study Design:
Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Relapse
Safety Issue:
No
Principal Investigator
Auayporn P. Nademanee, MD
Investigator Role:
Study Chair
Investigator Affiliation:
Beckman Research Institute
Authority:
United States: Federal Government
Study ID:
97133
NCT ID:
NCT00559104
Start Date:
October 1998
Completion Date:
July 2011
Related Keywords:
- Lymphoma
- stage III adult diffuse mixed cell lymphoma
- stage IV adult diffuse mixed cell lymphoma
- stage III adult immunoblastic large cell lymphoma
- stage IV adult immunoblastic large cell lymphoma
- stage IV mantle cell lymphoma
- stage III mantle cell lymphoma
- stage III adult diffuse large cell lymphoma
- stage IV adult diffuse large cell lymphoma
- stage III adult Burkitt lymphoma
- stage IV adult Burkitt lymphoma
- Lymphoma
- Lymphoma, Non-Hodgkin
- Lymphoma, Large-Cell, Immunoblastic
- Lymphoma, Mantle-Cell
Name | Location |
|---|
